Abiraterone, a steroidal cytochrome P 450 17a-hydroxylase-17,20-lyase inhibitor (CYP17), is currently undergoing phase II clinical trials as a potential drug for the treatment of androgen-dependent prostate cancer.
Form:
White Solid
Melting Point:
224-226 degrees C
Solubility:
Methanol